Clinical trial · Observational
Outcome Research of a European Registry Platform on Real-world Treatment Data of Patients with Advanced NMSC
NCT05741073CI-TRIAL-00087082recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This current registry study will analyze real-world data to address questions about disease characteristics and treatment patterns in NMSC patients based on the European NMSC-Registry. The overall objective is to describe characteristics, management and treatment outcomes for patients presenting with advanced NMSC (cSCC/BCC) or HR-cSCC in routine clinical practice, independent of treatments used across different European regions.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Basal Cell Carcinoma | Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.90 |
| Cutaneous Squamous Cell Carcinoma | Skin Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- resected HR-cSCC
- description
- Patients with resected HR-cSCC (Cohort 1) receiving only postoperative radiotherapy or watchful waiting
- label
- advanced cSCC
- description
- Patients with advanced cSCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 2)
- label
- advanced BCC
- description
- Patients with advanced BCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 3)
Primary outcomes (1)
- measure
- Real-world demographics in routine clinical practice
- timeFrame
- min. 2 years up to max 5 years of observation
- description
- To capture real-world demographics in routine clinical practice, independent of treatment used across different European regions in patients with advanced cSCC, advanced BCC, and completely resected HR-cSCC.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients aged ≥18 years at index date 2. Patients documented in the European NMSC-registry fulfilling EMR quality standard 3. Patients with resected HR-cSCC (Cohort 1) receiving only postoperative radiotherapy or watchful waiting OR Patients with advanced cSCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 2) OR Patients with advanced BCC who are not candidates for curative surgery/radiation in routine clinical practice (Cohort 3) Exclusion Criteria: 1\. Patients receiving treatment within a clinical trial.
References
Publications (0)
Data not yet available
No reference posted for this study.